Imagine using plants like a tiny factory to grow expensive medicines instead of using complex lab tanks. By tweaking the genetics of a specific plant, the team can grow high-quality proteins in fields or greenhouses. It's like farming a crop to harvest medicine instead of grain.
Pharmaceutical-grade recombinant proteins used in cell therapies are currently a bottleneck due to prohibitively high production costs and insufficient volumes.
A scalable biomanufacturing platform using transgenic Camelina Sativa to produce growth factors like Activin A, FGF-2, HSA, and TGF-β.
If you are a therapy manufacturer dealing with high production costs and insufficient volumes of growth factors — this project developed a plant-based platform that offers a 10-fold cost reduction. This allows for the scalable production of Xeno Free cell culture media.
If you are a food biotech company dealing with the high price of recombinant proteins for cell growth — this project developed a scalable biomanufacturing platform. It enables the production of pharmaceutical-grade proteins at a much lower cost.
If you are a cosmetics brand dealing with limited supply of active recombinant proteins — this project developed a plant-based system that provides a 25-fold yield increase. This ensures a steady, scalable supply of high-quality ingredients.
Based on available project data, the platform offers a 10-fold cost reduction compared to existing production methods.
Yes, the project focuses on scaling from prototype to industrial readiness using greenhouse and open field culture of Camelina Sativa to generate sufficient biomass.
The company utilizes a patented plant-based production platform and proprietary yield-enhancing genetic elements.
The project aims to obtain GMP qualification for growth factors to allow their use in clinical, commercial, food, and cosmetic fields.
Core Biogenesis aims to position itself as the European leader in plant-based biomanufacturing by 2025.
The project is led by a single French SME, Core Biogenesis, with a 100% industry ratio. This lean structure suggests a highly focused commercial drive, moving directly from a patented platform to industrial scale-up without the slower pace of academic partners.
Contact Core Biogenesis in France regarding their plant-based GF biomanufacturing platform.
Contact us to explore licensing or partnership opportunities with Core Biogenesis.
